Javing, Jewel Lizette .

HRN: 24-48-88  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/08/2024
CEFUROXIME 500MG (TAB)
02/08/2024
02/15/2024
PO
500mg
2x A Day
UTI;
Waiting Final Action 
02/08/2024
CEFTRIAXONE 1G (VIAL)
02/08/2024
02/15/2024
IV
2g
Q24
Uti
Waiting Final Action 
02/11/2024
CEFAZOLIN 1GM (VIAL)
02/11/2024
02/11/2024
IVTT
1 Gram
Once
Oophorocystectomy
Waiting Final Action 
02/13/2024
MUPIROCIN 2%, 15G (TUBE)
02/13/2024
02/20/2024
TOPICAL
2%
BID
S/p Explore Laparotomy Salphingectomy
Waiting Final Action 
02/13/2024
CEFUROXIME 500MG (TAB)
02/13/2024
02/20/2024
PO
500mg
BID
S/p Explore Laparotomy Salphingectomy
Waiting Final Action 
08/05/2024
AMPICILLIN 1GM (VIAL)
08/05/2024
08/12/2024
IV
2g
Q6
PPH Sec To Retained Placental Fragments
Waiting Final Action 
08/05/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
08/05/2024
08/12/2024
IV
500mg
Q8
PPH Sec To Retained Placental Fragments
Waiting Final Action 
08/08/2024
CEFUROXIME 1.5GM (VIAL)
08/08/2024
08/11/2024
IV
1.5g
Q8
S/p Completion Curettage
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: